Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADCE D01

Next Previous
Drug Profile

ADCE D01

Alternative Names: ADCE-D01

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADCendo
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Soft tissue sarcoma

Most Recent Events

  • 20 Apr 2026 ADCE D01 receives Orphan Drug status for Soft tissue sarcoma in USA
  • 20 Oct 2025 Phase-I/II clinical trials in Soft tissue sarcoma (Inoperable/Unresectable, Metastatic disease, Monotherapy, Second-line therapy or greater) in Germany, France (Parenteral) (NCT06797999) (CTIS-2024-516900-41-00)
  • 09 Oct 2025 ADCE D01 receives Fast Track designation for Soft tissue sarcoma [Parenteral] (Inoperable/Unresectable, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top